News und Analysen
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.
Financial
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
LivaNova to Wind Down Advanced Circulatory Support Business Unit
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Edison issues review on Worldwide Healthcare Trust (WWH): Scope for the trust to get back on track in 2024
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc